Markets were not hugely worried by predictions for a tough 2023 for Merck KGaA (MRK: DE), with the German company’s share price only marginally down late Thursday.
Merck made the predictions alongside presenting its financial results for 2022, which showed robust growth of sales and earnings.
" ...option of further accelerating our growth through potential acquisitions and in-licensing deals"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze